<DOC>
	<DOCNO>NCT02382536</DOCNO>
	<brief_summary>The purpose study compare in-line fluid pressure ( pressure fluid go tube ) leakage ( observation fluid around device ) subcutaneous infusion use two type infusion set . One infusion set investigational , developed BD , Quick-set ( Medtronic ) , commercially available . These infusion set use commercially available insulin pump deliver insulin diluent ( inactive liquid medication ) approximately 4 1/2 hour . During time pressure leakage continuously monitor .</brief_summary>
	<brief_title>Monitoring Infusion Pressure Insulin Infusion Sets Healthy Adults</brief_title>
	<detailed_description>This single center , open label study . Each subject receive 4 basal/bolus diluent infusion abdomen BD Scarlett Medtronic Quick-setÂ® ; 2 Scarlett infusion set 2 Quick-set infusion set . The order device placement randomize . After insertion , insulin diluent deliver rate 0.01 mL/hour ( equivalent volume rate 1.0 unit/hour U-100 insulin ) via insulin pump minimum 3 hour . After 3 hour basal infusion , bolus 0.1 mL ( equivalent 10 unit ) deliver via insulin pump basal infusion continue minimum 1 additional hour . At end final basal infusion period , infusion set tubing clamp mimic occlusion event allow run either occlusion alert ( `` delivery '' ) signal pump , minimum 30 minute , whichever come first . Infusion pressure data collect entire infusion period , include time tubing clamp . After removal device body , presence fluid application site skin ( Leakage ) determine visual assessment measure use gravimetric analysis , applicable .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Must age 1875 year age ( inclusive ) 2 . In stable health status acute significant illness , opinion investigator . 3 . Able read , write follow study instruction English . 4 . Able willing provide inform consent . 5 . Able willing complete study procedure . 1 . Pregnant ( selfattestation ) 2 . BMI &gt; 35 3 . Currently take antiplatelet therapy anticoagulant ( Use 81 mg per day aspirin permit ) 4 . History bleed disorder easy bruise 5 . Known blood borne infection 6 . Diabetes insulin therapy 7 . History recurrent dermatological condition skin disorder ( e.g . psoriasis , eczema ) 8 . Gross skin anomaly abnormality ( e.g . scar , stretch mark , discoloration , tattoo , superficial mass , ) locate close intend infusion site abdomen 9 . Subjects excessive hair abdomen unwilling excessive hair remove Site Staff 10 . Fear needle , history symptomatic low blood pressure history fainting ( syncope ) hypodermic injection 11 . History allergic reaction adhesive , metal , latex , plastic . 12 . Any condition PI designee deem pose risk subject study . 13 . Currently participate clinical investigation conflict one , participate study indication within prior 30 day Principal Investigator designee believe conflict outcome ability subject complete activity require study . 14 . Employed , currently serve contractor consultant BD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Insulin therapy</keyword>
	<keyword>insulin pump</keyword>
	<keyword>Infusion set</keyword>
</DOC>